Posts Tagged ‘vacuna SIDA’

Monday December 09th, 2013

EU Grants a Project to Test an Innovative HIV Vaccine Candidate in two phase I/IIa clinical trials

The four-year 6M€ European project iHIVARNA, funded by the European Commission, aims to successfully immunize antiretroviral-treated HIV-infected patients with 3 injections of the candidate universal HIV-TriMix-mRNA as an mRNA-based therapeutic vaccine with the final aim of improving the efficacy of therapeutic vaccination against HIV infection.

iHIVARNA is addressing the topic “Safety and efficacy of therapeutic vaccines” of the European Commission 7th Framework Programme Health 2013. The project brings together the expertise of a number of European groups (Spain, Belgium, and Netherlands) in dendritic cell targeting, rational design of immunogens, mRNA manufacturing and immuno-virological monitoring. This proposal continues the work in therapeutic vaccines performed in the last few years in the AIDS Research Unit of IDIBAPS leaded by Dr. Josep M Gatell and the Institute for AIDS Research IrsiCaixa. Dr. Felipe García, from IDIBAPS, is the coordinator of the iHIVARNA Consortium.

Read the rest of this entry »

Comments Closed
Wednesday January 02nd, 2013

A therapeutic dendritic cell vaccine for HIV-1 infection controls virus replication temporarily

Combination antiretroviral therapy (cART) is a success of modern medicine that greatly improves survival and quality of life of HIV-1–infected patients. The major drawback is that cART must be maintained indefinitely causing inconveniences to patients, potential long term toxicities and carrying elevated economical cost. Research teams across the globe work to find an alternative to “cART for life”, such as inducing HIV-1–specific immune responses to control viral replication after discontinuation of cART. Investigators from the AIDS and Infectious Diseases team of the Hospital Clínic/IDIBAPS at University of Barcelona, led by Dr. Josep Maria Gatell, report today in Science Translational Medicine the safety, tolerability, immunogenicity and virologic response results obtained with a new therapeutic vaccine candidate.


Watch it on Youtube in English.

Read the rest of this entry »

Comments Closed
Tuesday February 01st, 2011

Therapeutic AIDS vaccine designed by the HIVACAT reduces the viral load in the majority of AIDS patients

Therapeutic AIDS vaccine designed by the HIVACAT

The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments.  The final aim of the therapeutic vaccines will be to avoid a life long treatment with antiretroviral drugs.  The research team ‘Infectious Diseases and AIDS’ led by Dr. Josep Maria Gatell from IDIBAPS – Hospital Clínic   has developed using the brand HIVACAT, a model of the therapuetic vaccine based on the patient’s own  dendritic cells. This reduction in the viral load is still considered to be insuficient but it is the first therapeutic vaccine which has achieved a postive response in the majority of patients.

Read the rest of this entry »

Comments Closed